Literature DB >> 30859282

Hepatic sarcomatoid carcinoma: magnetic resonance imaging evaluation by using the liver imaging reporting and data system.

Nieun Seo1, Myeong-Jin Kim2, Hyungjin Rhee1.   

Abstract

OBJECTIVES: To evaluate how sarcomatoid carcinomas (SCs) would be classified on magnetic resonance imaging (MRI) by using the Liver Imaging Reporting and Data System (LI-RADS) and to assess imaging features of SC compared with other hepatic malignancies.
METHODS: We retrieved 184 patients with pathologically confirmed SC (n = 46), hepatocellular carcinoma (HCC, n = 92), and intrahepatic cholangiocarcinoma (iCCA, n = 46) diagnosed between January 2006 and December 2017. Two readers independently reviewed MRI according to LI-RADS v2017. Classification rate of SC, as probably or definitely malignant but not specific for HCC (LR-M), was calculated. LR-TIV (tumor in vein) was subclassified as either 5V or MV. MRI features were compared between SC, HCC, and iCCA and between SC of LR-M and non-LR-M categories.
RESULTS: Chronic liver disease was present in 71.7% (33/46) of patients with SC, and LI-RADS was applied for these patients. SC was classified as LR-M in 24 (72.7%) of 33 patients at risk. SCs that had been classified as LR-4/5/5V were significantly smaller (median, 1.9 cm; range, 1.0-4.2 cm) than SCs classified as LR-M/MV (median, 4.3 cm; range, 1.3-20.6 cm) on independent t test (p = 0.012). SCs commonly showed MRI features similar to iCCAs than to HCCs. Targetoid appearance and capsular retraction were more frequent in iCCA than in SC (p ≤ 0.009) on Pearson's chi-squared test or Fisher's exact test.
CONCLUSION: Most SCs can be classified as LR-M on MRI, but small lesions may be indistinguishable from HCCs. KEY POINTS: • Most sarcomatoid carcinomas (SCs) are classified as LR-M on MRI by using LI-RADS v2017. • SC showed various LR-M features similar to those of intrahepatic cholangiocarcinoma. • Size of LR-4/5/5V SC was significantly smaller than that of LR-M/MV SC.

Entities:  

Keywords:  Cholangiocarcinoma; Hepatocellular carcinoma; Liver neoplasms; Magnetic resonance imaging

Mesh:

Year:  2019        PMID: 30859282     DOI: 10.1007/s00330-019-06052-8

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  6 in total

Review 1.  Sarcomatoid hepatocellular carcinoma versus conventional hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Tian-Run Lv; Hai-Jie Hu; Parbatraj Regmi; Fei Liu; Fu-Yu Li
Journal:  J Cancer Res Clin Oncol       Date:  2022-02-24       Impact factor: 4.553

2.  Computed Tomography Features and Clinicopathological Characteristics of Gastric Sarcomatoid Carcinoma.

Authors:  Yi-Yang Liu; Pan Liang; Kai-Xiang Feng; Kui-Sheng Chen; Song-Wei Yue; Jiang Ji; Wei-Wei Li; Xi-Tong Zhao; Jian-Bo Gao
Journal:  Front Oncol       Date:  2020-08-11       Impact factor: 6.244

3.  Primary Liver Sarcomatoid Carcinoma: A Case Series and Literature Review.

Authors:  Wei Ji; Yunlong Xing; Jinshu Ma; Zhuo Zhao; Hongqin Xu; Shuang Zheng; Wei Li; Xu Li
Journal:  J Hepatocell Carcinoma       Date:  2021-09-07

Review 4.  A retrospective study on the clinical and pathological features of hepatic sarcomatoid carcinoma: Fourteen cases of a rare tumor.

Authors:  Shuoshuo Ma; Chunshuang Li; Yang Ma; Xiaolei Wang; Dengyong Zhang; Zheng Lu
Journal:  Medicine (Baltimore)       Date:  2022-08-05       Impact factor: 1.817

5.  MRI Features of Hepatic Sarcomatoid Carcinoma Different From Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Authors:  Hongbin Zhang; Siyuan Chai; Lintao Chen; Yubizhuo Wang; Yongna Cheng; Quan Fang; Guosen Wu; Xiangming Wang; Wenjie Liang; Wenbo Xiao
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244

6.  Clinicopathological characteristics and surgical outcomes of sarcomatoid hepatocellular carcinoma.

Authors:  Jian-Ping Wang; Zhi-Gang Yao; Ya-Wen Sun; Xi-Han Liu; Feng-Kai Sun; Cun-Hu Lin; Fu-Xin Ren; Bei-Bei Lv; Shuai-Jun Zhang; Yang Wang; Fan-Ying Meng; Shun-Zhen Zheng; Wei Gong; Jun Liu
Journal:  World J Gastroenterol       Date:  2020-08-07       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.